Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million
Dear Ocumetics Investors,
I am thrilled to share some exciting news that marks a significant milestone for our company and our mission to revolutionize eye care technology. I am pleased to announce that Ocumetics has successfully closed the first tranche of our secured convertible debenture financing with an aggregate face value of $3,000,000. This debenture, issued with a 6% original issue discount, has provided us with net proceeds of $2,820,000, less associated lender expenses. Our total offering aims to raise up to $4,000,000, and we are confident that we will close the remaining amount in one or more subsequent tranches within the next 30 days.
Moving Towards First-In-Human Trials
This substantial financial milestone allows us to immediately advance our ground-breaking technology to the next critical phase: our first-in-human trials. These trials, scheduled to take place later this year in the Dominican Republic, represent a pivotal step in demonstrating the potential of our innovative eye care solutions to improve vision and quality of life for countless individuals.
Our team has been diligently preparing for this moment, and we are ready to move forward with the necessary preparations and regulatory approvals to ensure the success of these trials. This funding will enable us to finalize these preparations and take the essential steps to bring our technology to the forefront of medical science.
The Path Ahead
The first-in-human trials are not just a technical requirement; they are a testament to our commitment to innovation and our dedication to providing life-changing solutions. These trials will provide us with invaluable data and insights, helping us refine our technology and move closer to our goal of commercialization.
In the coming weeks, I will share more detailed information about the specific activities and milestones we aim to achieve through these trials. Our team is incredibly motivated and focused, and we believe that these trials will showcase the efficacy and safety of our technology, setting the stage for broader clinical applications and market entry.
Strengthening Our Financial Position
The secured convertible debenture financing has been strategically structured to ensure that we have the necessary capital to drive our projects forward without compromising our financial stability. By securing this financing, we are reinforcing our commitment to responsible financial management while aggressively pursuing our research and development goals.
This funding also reflects the confidence and trust that our investors have in Ocumetics and our vision for the future. We are grateful for your continued support and belief in our mission. Your investment is instrumental in helping us achieve our objectives and make a tangible difference in the field of ophthalmology.
Key Highlights Precision molds received for manufacturing of new optimized accommodating intraocular lenses Production and testing of next-generation lenses now underway New lens design incorporates insights from Group One First-in-Human study Group Two preclinical surgeries targeted for early Q3 2026 FDA Investigational Device Exemption (IDE) preparation advancing Calgary, Canada – TheNewswire – May 12, 2026
Calgary, Alberta – TheNewswire – April 29, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a private placement (the “Offering”) of up to 2,800,000 units of the Corporation (“Units”) at a price of $0.55 per Unit for gross proceeds of up to
Key Highlights Vision performance: Clinical outcomes exceed expectations, with all patients experiencing continuing vision improvements Safety profile: Continues to meet expectations Quality-of-life improvements: Anecdotally, all patients reported life changing results from lens implantations Technology validation: Results reinforce the expected performance of Ocumetics’ inaugural accommodating intraocular lens Momentum: Forward momentum continues, with lens design enhancements
Key Highlights No material change: There is no material change in the business affairs of Ocumetics. Attendance at ASCRS: Productive ASCRS meetings with major global ophthalmic leaders. Clinical and development momentum: Feedback supported positive results from the First-in-Human (FIH) Group 1 study while the Company advances toward Group 2 patient recruitment and upcoming surgeries. Regulatory
